Kessler RC, et al. The Epidemiology of Major Depressive DisorderResults From the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–105.
Article
PubMed
Google Scholar
Kornstein Susan G, Schneider Robert K. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl6):18–25.
Google Scholar
Young Juan J, Bruno D, Pomara N. A review of the relationship between proinflammtory cytokines and major depressive disorder. J Affect Disord. 2014;169:15–20.
Article
PubMed
Google Scholar
Azar R, Mercer D. Mild depressive symptoms are associated with elevated C-reactive protein and proinflammatory cytokine levels during early to midgestation: a prospective pilot study. J Womens Health. 2013;22(4):385–9.
Article
Google Scholar
Miller Andrew H, Maletic V, Raison Charles L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Simon NM, et al. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol. 2008;18(3):230–3.
Article
CAS
PubMed
Google Scholar
Bonaccorso S, et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72(3):237–41.
Article
CAS
PubMed
Google Scholar
O'Brien Sinead M, et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res. 2007;41(3-4):326–31.
Article
PubMed
Google Scholar
Raison Charles L, et al. A randomized controlled trial of the tumor necrosis factor antagonist Infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiat. 2013;70(1):31–41.
Article
CAS
Google Scholar
Langley Richard G, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457–65.
Article
CAS
PubMed
Google Scholar
Akhondzadeh S, et al. Clinical trial of adjunctive Celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26(7):607–11.
Article
CAS
PubMed
Google Scholar
Müller N. The role of anti-inflammatory treatment in psychiatric disorders. Psyhicatria Danubina. 2013;25(3):292–8.
Google Scholar
Fields C, et al. Celecoxib or Naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatry. 2012;20(6):505–13.
Article
PubMed
PubMed Central
Google Scholar
Köhler Ole, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects A Systematic Review and Meta-analysis of Randomized Clinical Trials. 2014, JAMA Psychiatry, p. doi:10.1001/jamapsychiatry.2014.1611.
Bleakley K, Yamanishi Y. Supervised prediction of drug-target interactions using bipartite local models. Bioinformatics. 2009;25(18):2397–403.
Article
CAS
PubMed
PubMed Central
Google Scholar
Keiser Michael J, et al. Predicting new molecular targets for known drugs. Nature. 2009;462:175–81.
Article
CAS
PubMed
PubMed Central
Google Scholar
Faulon J-L, et al. Genome scale enzyme-metabolite and drug–target interaction predictions using the signature molecular descriptor. Bioinformatics. 2008;24(2):225–33.
Article
CAS
PubMed
Google Scholar
Yamanishi Y, et al. Prediction of drug–target interaction networks from the integration of chemical and genomic spaces. Bioinformatics. 2008;24(13):i232–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lamb J, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929–35.
Article
CAS
PubMed
Google Scholar
Campillos M, et al. Drug target identification using side-effect similarity. Science. 2008;321(5886):263–6.
Article
CAS
PubMed
Google Scholar
Takarabe M, et al. Drug target prediction using adverse event report systems: a pharmacogenomic approach. Bioinformatics. 2012;28:i611–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kuhn M, et al. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol. 2010;6:343.
Article
PubMed
PubMed Central
Google Scholar
Whiskey E, Taylor D. Pramipexole in unipolar and bipolar depression. Psychiatric Bulletin. 2004;28:438–40.
Article
Google Scholar
Barber J. Examining the use of tramadol hydrochloride as an antidepressant. Exp Clin Psychopharmacol. 2011;19(2):123–30.
Article
CAS
PubMed
Google Scholar
Lapidus Kyle AB, Soleimani L, Murrough James W. Novel gluatmatergic drugs for the treatment of mood disorders. Neuropsychiatric Disease and Treatment. 2013;9:1101–12.
PubMed
PubMed Central
Google Scholar
Stein Dan J, et al. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008;18(6):422–30.
Article
CAS
PubMed
Google Scholar
Song F, et al. Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: differential expression of neurotrophic and gliotrophic factors. J Neuroimmunol. 2013;262(1-2):11–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Caragnano M, et al. Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. J Neuroimmunol. 2012;245(1-2):93–7.
Article
CAS
PubMed
Google Scholar
Arnon R, Aharoni R. Neurogenesis and neuroprotection in the CNS – fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders. Mol Neurobiol. 2007;36:245–53.
Article
CAS
PubMed
Google Scholar
Basso Ana M, et al. Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav Brain Res. 2009;198(1):83–90.
Article
CAS
PubMed
Google Scholar
Calapai G, et al. Montelukast-Induced Adverse Drug Reactions: A Review of Case Reports in the Literature. Pharmacology. 2014;94(1-2):60–70.
Article
CAS
PubMed
Google Scholar
Hoeffer Charles A, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neuroscience. 2010;33(2):67–75.
Article
CAS
Google Scholar
Halloran J, et al. Chronic inhibition of mTOR by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience. 2012;223:102–13.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li N, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–64.
Article
CAS
PubMed
PubMed Central
Google Scholar
De Bosscher K, Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol. 2009;23:281–91.
Article
PubMed
Google Scholar
Anacker C, et al. The glucocorticoid receptor: Pivot of depression and of antidepressant treatment? Psychoneuroendocrinology. 2011;36(3):415–25.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pariante Carmine M. Risk factors for development of depression and psychosis. Annals of the New York Acadamey of Sciences. 2009;1179:144–52.
Article
CAS
Google Scholar
David Denis J, et al. Neurogenesis-Dependent and -Independent Effects of Fluoxetine in an Animal Model of Anxiety/Depression. Neuron. 2009;62(4):479–93.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dinan TG, et al. Dexamethasone augmentation in treatment-resistant depression. Acta Pychiatrica Scandinavica. 1997;95:58–61.
Article
CAS
Google Scholar
Bouwer C, et al. Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolaemia: a case series. Depress Anxiety. 2000;12(1):44–50.
Article
CAS
PubMed
Google Scholar
DeBattista C, et al. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2000;157(8):1334–7.
Article
CAS
PubMed
Google Scholar
Liblau R. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role. J Neurol Sci. 2009;287(sup 1):S17–23.
Article
CAS
PubMed
Google Scholar
Ziemssen T, Schrempf W. Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol. 2007;79:537–70.
Chen Man V, Reuben M, Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci. 2003;215(1-2):37–44.
Article
CAS
PubMed
Google Scholar
Lee B-H, Kim Y-K. The Roles of BDNF in the Pathophysiology of Major Depression and in Antidepressant Treatment. Psychiatry Investigation. 2010;7(4):231–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Powell Jonathan D, et al. Regulation of Immune Responses by mTOR. Annual Reviews Immunology. 2012;30:39–68.
Article
CAS
Google Scholar
Graber Tyson E, McCamphill Patrick K, Sossin Wayne S. A recollection of mTOR signaling in learning and memory. Learn Mem. 2013;20(10):518–30.
Siddiqui A, Hanson I, Andersen Julie K. MAO-B elevation decreases parkin's ability to efficiently clear damaged mitochondria: protective effects of rapamycin. Free Radic Res. 2012;46(8):1011–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Toth Bela E, et al. Role of peripheral and brain-derived dopamine (DA) in immune regulation. Advances in Neuroimmune Biology. 2012;3:111–55.
Google Scholar
Ilani T, Strous Rael D, Fuchs S. Dopaminergic regulation of immune cells via D3 dopamine receptor: A pathway mediated by activated T cells. FASEB J. 2004;18(13):1600–2.
CAS
PubMed
Google Scholar
Torres-Rosas R, et al. Dopamine mediates vagal modulation of the immune system by electroacupuncture. Nat Med. 2014;20:291–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nagai Y, et al. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology. 1996;46(3):791–5.
Article
CAS
PubMed
Google Scholar
IIani T, et al. A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci U S A. 2001;98(2):625–8.
Article
Google Scholar
Montgomery Stuart A. The under-recognized role of dopamine in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2008;23(2):63–9.
Article
CAS
PubMed
Google Scholar
O'Connell Peta J, et al. A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood. 2006;107(3):1010–7.
Article
PubMed
PubMed Central
Google Scholar
Leon-Ponte M, Ahern Gerard P, O'Connell Peta J. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood. 2007;109(8):3139–46.
Article
CAS
PubMed
PubMed Central
Google Scholar
Baganz Nicole L, Blakely Randy D. A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Nerosci. 2013;4(1):48–63.
Article
CAS
Google Scholar
Maes M. The immunoregulatory effects of antidepressants. Hum Psychopharmacol. 2001;16:95–103.
Article
CAS
PubMed
Google Scholar
Sacre S, et al. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis and Rheumatology. 2019;62(3):683–93.
Article
Google Scholar
Pauwels, Edouard, Stoven, Véronique and Yamanishi, Yoshihiro. Predicting drug side-effect profiles: a chemical fragment-based approach. 2011, BMC Bioinformatics, pp. doi: 10.1186/1471-2105-12-169.
Martiny Virginie Y, et al. Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6. Bioinformatics. 2015;31(24):3930–7.
CAS
PubMed
Google Scholar
Kalb Robert E, et al. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatology. 2015;151(9):961–9.
Article
CAS
PubMed
Google Scholar